Hoersholm, Denmark, September 17, 2018 - Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) ("OV" or "the Company") announce the fourth update from the ongoing LiPlaCis ® Phase 2 study. In the ...
Hørsholm, Denmark (2 April 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced the submission of a premarket approval application (PMA) to the U.S. Food and Drug ...
Hørsholm, Denmark (5 July 2021) — Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has provided a positive administrative ...
Allarity Therapeutics, a Phase 2 clinical-stage pharmaceutical company, announced the acceptance of its patent application in Australia for the Drug Response Predictor (DRP®) companion diagnostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results